Fisher Asset Management LLC cut its position in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) by 13.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 259,024 shares of the company’s stock after selling 39,481 shares during the period. Fisher Asset Management LLC’s holdings in Dyne Therapeutics were worth $4,173,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently made changes to their positions in DYN. Russell Investments Group Ltd. increased its position in shares of Dyne Therapeutics by 141.8% during the third quarter. Russell Investments Group Ltd. now owns 255,190 shares of the company’s stock worth $4,111,000 after purchasing an additional 149,637 shares in the last quarter. Pictet Asset Management Holding SA raised its stake in Dyne Therapeutics by 7.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 20,805 shares of the company’s stock valued at $335,000 after purchasing an additional 1,433 shares during the last quarter. Alps Advisors Inc. raised its stake in Dyne Therapeutics by 48.1% in the 3rd quarter. Alps Advisors Inc. now owns 247,403 shares of the company’s stock valued at $3,986,000 after purchasing an additional 80,321 shares during the last quarter. CenterBook Partners LP lifted its holdings in Dyne Therapeutics by 167.7% in the 3rd quarter. CenterBook Partners LP now owns 57,650 shares of the company’s stock valued at $929,000 after purchasing an additional 36,112 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Dyne Therapeutics in the 3rd quarter valued at $154,000. 96.68% of the stock is owned by institutional investors and hedge funds.
Dyne Therapeutics Price Performance
Shares of DYN stock opened at $16.70 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 12.99 and a quick ratio of 12.99. The firm’s 50-day moving average is $16.81 and its two-hundred day moving average is $19.32. Dyne Therapeutics, Inc. has a 12 month low of $14.00 and a 12 month high of $27.31. The company has a market capitalization of $3.13 billion, a PE ratio of -4.60 and a beta of 1.22.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same quarter in the prior year, the business posted ($0.76) EPS. Analysts predict that Dyne Therapeutics, Inc. will post -3.81 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts have issued reports on DYN shares. Stifel Nicolaus set a $37.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Jefferies Financial Group reiterated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. HC Wainwright decreased their price target on shares of Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, September 30th. Royal Bank Of Canada lowered their price target on shares of Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 9th. Finally, Piper Sandler restated an “overweight” rating and set a $47.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.29.
Check Out Our Latest Stock Report on Dyne Therapeutics
Insider Activity
In related news, insider Douglas Kerr sold 3,745 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $24.35, for a total value of $91,190.75. Following the transaction, the insider directly owned 163,854 shares in the company, valued at approximately $3,989,844.90. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Cox sold 5,658 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the transaction, the chief executive officer owned 357,507 shares in the company, valued at $6,749,732.16. This represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 14,000 shares of company stock worth $285,151 over the last quarter. 9.46% of the stock is currently owned by corporate insiders.
Dyne Therapeutics Profile
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.
Recommended Stories
- Five stocks we like better than Dyne Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report).
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
